PCORI KIDCARE Rare Disease Kawasaki comparative effectiveness Skip To Content

Study ID: PCORI KIDCARE Rare Disease Kawasaki comparative effectiveness

Title:

PCORI Rare Disease comparative effectiveness clinical trial to compare 2nd IVIG vs. infliximab for patients with IVIG resistance

Description:
KIDCARE is a 3-year (2.75-years of enrollment), Phase III, two-arm, randomized, multi-center, treatment study. The goal of this study is to compare infliximab to a second intravenous immunoglobulin (IVIG) infusion for treatment of persistent or recrudescent fever in children with KD who fail to become afebrile after the first IVIG infusion.
Location:
Sioux Falls Region
Principal Investigator:
Archana Chatterjee, MD, PhD
Disease:
Other, Heart
Stage:
Unknown
Status:
Active - Open to Accrual

For more information, call or email Bismarck Clinical Research at (701) 323-5760, Fargo and Bemidji Clinical Research at (701) 234-5890, or Sioux Falls Clinical Research at (605) 328-1368.